Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.

People are discussing hair loss treatments, including minoxidil, finasteride, and RU58841, to turn vellus hairs into terminal hairs. Some users also mention using antibiotics, oral minoxidil, dutasteride, DHT blockers, biotin, and natural remedies like onion juice and seeds to improve hair growth.

The user is using Minoxidil, finasteride, Nizoral, and dermarolling for hair loss but is not seeing results. They are considering trying a product called "capilia longa" for beard growth and are questioning its effectiveness.

A 21-year-old is experiencing hairline recession and is using finasteride, saw palmetto, gelatin, topical minoxidil with retinoic acid, derma stamping, and scalp massage to address it. Suggestions include adding oral minoxidil, vitamin D3 with K2, and maintaining the current regimen for a year.

The conversation discusses hair loss and hairstyles for balding men, with some users suggesting treatments like Minoxidil, finasteride, RU58841, and dutasteride. The focus is on embracing unique hairstyles instead of shaving, with mixed opinions on their appeal.

MCL-1 is important for hair follicle stem cell survival, but its impact on human hair regrowth is unclear. Minoxidil and finasteride are the main treatments, with doubts about new discoveries leading to effective human solutions soon.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

The user has been using finasteride, minoxidil, ketoconazole shampoo, needling, and experimenting with retinol cream to treat hair loss. Despite these treatments, they observe many small vellus hairs that do not grow longer.

The conversation discusses various hair loss treatments, including pyrilutamide, RU58841, topical dutasteride, oral minoxidil, and oral finasteride/dutasteride. It also mentions potential treatments like PP405, Verteporfin, GT20029, and AMP303.

Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hair loss are unclear.

Hair loss is causing distress and self-esteem issues, with discussions on treatments like finasteride, minoxidil, and hair transplants. Some suggest topical treatments or lifestyle changes, while others stress the importance of confidence and self-acceptance.

Some individuals experience side effects from 5AR inhibitors like finasteride and are considering hair transplants without these medications, with some opting for surgeons like Dr. Zarev. Others are exploring alternative treatments and waiting for new medications in development, while some discuss managing side effects through lifestyle changes or additional medications.

Thin, short hairs often appear in areas of hair loss but may not grow fully despite treatments like finasteride. Some users consider additional treatments like microneedling or hair transplants.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

The conversation discusses the potential of new hair loss treatments, with a focus on pyrilutamide, gt20029, and topical alfatradiol, and the possibility of improving their effectiveness through methods like increased concentration and microneedling. Dutasteride is also mentioned as a stronger option.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

A 25-year-old experiencing hair thinning all over the body and head, despite using minoxidil and having low vitamin D levels, is advised to seek a second opinion from a dermatologist specializing in hair loss. The likely diagnosis is diffuse alopecia areata, which may require treatment with a JAK inhibitor.

A 30-year-old man shares his successful hair loss protocol, which includes finasteride, Nizoral shampoo, low-level laser therapy, microneedling, and past use of oral minoxidil. He plans to consider dutasteride and possibly hair transplants in the future, while advising caution with crown transplants before age 35.

Treatments for hair loss, such as minoxidil, finasteride, and RU58841; humorous posts about hair loss; and the choice to stop using treatments in exchange for a different look.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The conclusion of the conversation is that the user has tried various medications and treatments for hair loss, including minoxidil, finasteride, microneedling, and nizoral shampoo, but has not seen any progress. They have decided to shave their head. Other users suggest options such as hair transplants, RU58841, hair units, and scalp micropigmentation.

Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.

The user experienced rapid diffuse hair thinning for five years despite no signs of AGA or miniaturization. They tried finasteride and oral minoxidil without success and have checked thyroid, iron, and vitamin D levels.

A user shared their experience with hair loss treatments, including topical minoxidil, finasteride, RU58841, and microneedling, noting significant hair regrowth except at the hairline. They plan to start oral minoxidil and switch to a combination treatment, while another user mentioned that some miniaturized hairs may not fully recover.